Ostalo
Evolution of Melanocytic Nevi under Vemurafenib, Followed by Combination Therapy with Dabrafenib and Trametinib for Metastatic Melanoma
Calin Giurcaneanu
; Carol Davila University of Medicine and Pharmacy, Bucharest Department of Dermatology, Elias Emergency University Hospital, , Bucharest
Cornelia Nitipir
; Carol Davila University of Medicine and Pharmacy, Bucharest Department of Oncolog, Elias Emergency University Hospital, , Bucharest
Liliana Gabriela Popa
; Department of Dermatology, Elias Emergency University Hospital, , Bucharest
Ana Maria Forsea
; Carol Davila University of Medicine and Pharmacy, Bucharest Department of Dermatology, Elias Emergency University Hospital, , Bucharest
Ioana Popescu
; Department of Dermatology, Elias Emergency University Hospital, , Bucharest
Roxana Silvia Bumbacea
; Carol Davila University of Medicine and Pharmacy, Bucharest Department of Dermatology, Elias Emergency University Hospital, , Bucharest
Sažetak
ABSTRACT Treatment of advanced melanoma with selective BRAF and MEK inhibitors is associated with a series of mucocutaneous side effects, among which morphological changes in preexisting nevi and the development of new melanocytic lesions, both benign and malignant.
Objective was to describe the changes observed in melanocytic nevi under vemurafenib therapy, followed by combination therapy with dabrafenib and trametinib for metastatic melanoma.
The melanocytic lesions of a 51-year-old Caucasian male patient diagnosed with stage IV melanoma were monitored both clinically and dermoscopically throughout vemurafenib, followed by combined treatment with dabrafenib and trametinib.
The 65 monitored nevi presented different behaviors under vemurafenib treatment: 18 reticular nevi, 9 reticular-homogenous nevi, 3 reticular-globular nevi, and 2 globular nevi showed a diffuse decrease in pigmentation. Ten reticular nevi remained unchanged, while the rest of the nevi, independent of the dermoscopic pattern, presented a gradual increase in pigmentation. On the other hand, under dabrafenib and trametinib treatment 57 of these nevi showed gradual decrease in pigmentation and central involution, while 7 reticular nevi and 1 globular nevus remained unchanged; none of the monitored nevi increased in pigmentation nor presented new globules following this combination therapy.
Systematic total body skin examination is mandatory in patients receiving BRAF inhibitors. The divergent course of melanocytic nevi during vemurafenib vs. dabrafenib and trametinib therapy remains to be elucidated by further research.
KEY WORDS: melanoma; pigmented nevus; dermoscopy; vemurafenib
Ključne riječi
Hrčak ID:
142140
URI
Datum izdavanja:
21.7.2015.
Posjeta: 942 *